1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow JNJ-40346527: new trials by email Literature Review of JNJ-40346527 trials Research Report on JNJ-40346527
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia Edicotinib, Pharmacokinetic Study - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 3 | 2018-10-05 | 2021-12-02 |
| A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy JNJ-40346527, Placebo - Arthritis, Rheumatoid | Phase 2 | Completed | Janssen Research & Development, LLC | 96 | 2012-07-01 | 2014-04-08 |
Arthritis, Rheumatoid (1) · Leukemia, Myeloid, Acute (1)
Janssen Research & Development, LLC (1) · OHSU Knight Cancer Institute (1)
Argentina (1) · Bulgaria (1) · Chile (1) · Czechia (1) · Hungary (1) · Poland (1) · Russia (1) · Singapore (1) · South Korea (1) · Ukraine (1) · United States (1)
Elie Traer, MD (1)